Incorporating information about cost-effectiveness into evidence-based decision-making: The evidence-based practice center (EPC) model

Medical Care

Volumn 43, Issue 7 SUPPL., 2005, Pages

  Helfand, Mark ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Decision making; Evidence based medicine

Indexed keywords

COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; MANAGEMENT; PUBLIC HEALTH SERVICE; REVIEW; STATISTICAL MODEL; UNITED STATES;

COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; MODELS, ECONOMETRIC; POLICY MAKING; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES; UNITED STATES PUBLIC HEALTH SERVICE;

EID: 22944465394     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Matchar DB, Patwardhan MB, Samsa GP. Making evidence-based practice improvement more than a comforting sentiment. Am J Med. 2003;115:407-409.
2. Matchar DB, Samsa GP. The role of evidence reports in evidence-based medicine: a mechanism for linking scientific evidence and practice improvement. Jt Comm J Qual Improv. 1999;25:522-528.
3. Scheingold SH. Approaching the 10 year anniversary of evidence-based coverage decisions: reality checks. 2003.
4. Russell LB. The methodologic partnership of effectiveness reviews and cost-effectiveness analysis. Am J Prev Med. 2001;20(suppl):10-12.
5. Luce BR. Where does outcomes research fit into evidence-based health care decision-making? MEDTAP Research News. 2004;VII:1, 7.
6. Wertheimer AI. Pharmaceutical cost effectiveness review methods. Med Care. 2004.
7. Eccles M, Mason J, Freemantle N. Developing valid cost effectiveness guidelines: a methodological report from the north of England evidence based guideline development project. Quality in Health Care. 2000;9:127-132.
8. Mason J, Eccles M, Freemantle N, et al. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. Health Policy. 1999;47:37-52.
9. Anis AH, Rahman T, Schechter MT. Using pharmacoeconomic analysis to make drug insurance coverage decisions. Pharmacoeconomics. 1998;13:119-126.
10. Saha S, Hoerger TJ, Pignone MP, et al. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med. 1999;20(suppl):36-43.
11. Carande-Kulis VG, Maciosek MV, Briss PA, et al. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services. Am J Prev Med. 2000;18(suppl):75- 91.
12. Fronstin P, Robertson D. Making coverage decisions. EBRI Education and Research Fund Newsletter. 2003:1-5.
13. Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490-1494.
14. Danese MD, Powe NR, Sawin CT, et al. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA. 1996;276:285-292.
15. US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. Baltimore: Williams & Wilkins; 1996.
16. Clancy CM, Kamerow DB, Hoadley JF. Evidence-based medicine meets cost-effectiveness analysis. JAMA. 1996;276:329-330.
17. Woolf S. Evidence-Based Practice Center Procedure Manual. Rockville: US Department of Health & Human Services, Agency for Healthcare Research & Quality; 1997.
18. Harris RP, Helfand M, Woolf SH, et al. Methods of the third US Preventive Services Task Force. Am J Prev Med. 1999;20(suppl):21-35.
19. Tunis S, Stryer D, Clancy C. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. 2003;290:1624-1632.
20. Samsa GP, Govert J, Matchar DB, et al. Use of data from nonrandomized trial designs in evidence reports: an application to treatment of pulmonary disease following spinal cord injury. J Rehabil Res Dev. 2002;39:41-52.
21. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet. 2004;363:1728-1731.
22. Nelson HD, Morris CD, Kraemer DF, et al. Osteoporosis in Postmenopausal Women: Diagnosis and Monitoring. Evidence Report/Technology Assessment: Number 28. Rockville, MD: Agency for Healthcare Research and Quality, AHRQ Publication Number 01-E031; 2001.
23. Concato J, Horwitz RI. Beyond randomized versus observational studies. Lancet. 2004;363:1660-1661.
24. Shih YT, Han S, Cantor SB. Impact of generic drug entry on cost-effectiveness analysis. Med Decis Making. 2005;25:71-80.
25. Reinhardt U. Making economic evaluations respectable. Soc Sci Med. 1997;45:555-562.
26. Russell L. Cost-Effectiveness Analysis. Committee on Health and Behavior: Research, Practice, and Policy. Institute of Medicine; 1999.
27. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
28. Clinical guideline, part 1. Screening for thyroid disease. American College of Physicians. Ann Intern Med. 1998;129:141-143.
29. Summaries for patients. Screening for thyroid disease: a recommendation from the US Preventive Services Task Force. Ann Intern Med. 2004;140:20.
30. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238.
31. Light RJ, Pillemer DP. Summing Up: The Science of Reviewing Research Cambridge: Harvard University Press; 1984.
32. Fendrick AM, Chernew ME, Hirth RA, et al. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med. 1995;123:260-268.
33. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or initial therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology. 1996;110:72-83.
34. Ganiats TG. Do cost-effectiveness analyses cause you dyspepsia? J Fam Pract. 1997;44:541-542.
35. Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2002;137:96-104.
36. Rothwell PM. Treating individuals 1: external validity of randomized controlled trials: 'To whom do the results of this trial apply'? Lancet. 2005;365:82-93.
37. Royle P, Waugh N. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the NICE appraisal system. Health Technol Assess. 2003;7:1-70.
38. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value in Health. 2003;6:9-17.